The RehaARM-Robot
DeviceRobot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
Other names: Robot-assisted therapy for the shoulder
NCT Number: NCT02321254
The aim of this study is to assess the clinical effectiveness of the RehaARM-robot and to determine the feasibility of including robotic therapy in daily rehabilitation programmes, after stroke. Additionally, we aim to investigate the acceptance of this intervention from patients and therapists. A total of 10 patients will be recruited in this study, all the patients will receive 1 hour of standard therapy together with 45 min of robot therapy every day. The robot therapy will last 45 minutes, for 15 consecutive days within a maximum period of four weeks. Additional 15 minutes are required for placing surface electrodes on the shoulder and patient preparation. The study will include passive and active shoulder training of four movements: Horizontal abduction/adduction, abduction/adduction, internal/external rotation and flexion/extension. The passive part lasts 10 minutes and the active part 35 minutes.
Looking for future studies?
Notify Me18 year–90 year
All sexes
Interventional
Phase 1
FerRobotics Compliant Robot Technology GmbH, Linz, Austria
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
Other names: Robot-assisted therapy for the shoulder
Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
Time frame: 3 weeks (15 sessions)
Motor function of the upper limb is measured by means of the Upper Extremity Motor Assessment of the Fugl-Meyer Assessment Scale.
Time frame: 3 weeks (15 sessions)
FIM is an 18-item scale that assesses patient's disability and medical rehabilitation functional outcome (A total of 126 points).
Time frame: 3 weeks (15 sessions)
It assesses the ability of subjects to reach an object (a cone). The cone is placed at a 4-cm distance and after at a 30-cm distance from the subject. The subject is asked to reach and grab the cone if possible. The observer evaluates the quality of reaching instead of the grip strength ( A total of 36 points).
Time frame: 3 weeks (15 sessions)
Spasticity is measured using the MAS of five muscles: Pectoralis major, biceps, wrist flexors, flexor digitorum superficialis, flexor digitorum profundus (Total of 20 points).
Time frame: 3 weeks (15 sessions)
It measures the dexterity of the hand. Patient should insert 9 pins in the board. There are 9 pins. The number of pins inserted in 50 min are registered or if the patient inserted 9 pins, then the time is registered.
Time frame: 3 weeks (15 sessions)
Active range improvement for shoulder abduction and flexion are measured using the Tyromotion Pablo System.
Time frame: 3 weeks (15 sessions)
A higher number of repetitions is a paramount for neuroplasticity. The ability of subjects to execute a larger of number of motor task repetitions with the robot after the treatment is measured.
Time frame: 3 weeks (15 sessions)
Smoothness is a measure of human movement coordination. Improvement of smoothness after the treatment is measured.
Time frame: 3 weeks (15 sessions)
Time frame: 3 weeks (15 sessions)
IRCCS San Camillo, Venezia, Italy
Other
A Pilot Study of Active, Robot-assisted Therapy for Shoulder Rehabilitation After Stroke, Using Myoelectric Signals
Acronym: MyoReArm
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsNCT06750692
Brain Diseases, Cardiovascular Diseases
Afyonkarahisar, Turkey (Türkiye)
View Trial DetailsNCT04992195
Alzheimer Disease, Arterial Thromboembolism
Hong Kong
View Trial Details